BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baunwall SMD, Terveer EM, Dahlerup JF, Erikstrup C, Arkkila P, Vehreschild MJ, Ianiro G, Gasbarrini A, Sokol H, Kump PK, Satokari R, De Looze D, Vermeire S, Nakov R, Brezina J, Helms M, Kjeldsen J, Rode AA, Kousgaard SJ, Alric L, Trang-Poisson C, Scanzi J, Link A, Stallmach A, Kupcinskas J, Johnsen PH, Garborg K, Rodríguez ES, Serrander L, Brummer RJ, Galpérine KT, Goldenberg SD, Mullish BH, Williams HR, Iqbal TH, Ponsioen C, Kuijper EJ, Cammarota G, Keller JJ, Hvas CL. The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey. Lancet Reg Health Eur 2021;9:100181. [PMID: 34693388 DOI: 10.1016/j.lanepe.2021.100181] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Brenig A, Broekaert I, Gerner P, Posovszky C, Hünseler C, Joachim A. Microbiome analysis and fecal microbiota transfer in pediatric gastroenterology - a structured online survey in German-speaking countries. Int J Colorectal Dis 2023;38:59. [PMID: 36867263 DOI: 10.1007/s00384-023-04351-7] [Reference Citation Analysis]
2 Hocking L, Ianiro G, Leong RW, Iqbal T, Kao D, Cabling M, Stockwell S, Romanelli RJ, Marjanovic S. Faecal microbiota transplantation for recurrent C. difficile infections: challenges and improvement opportunities for clinical practice and healthcare systems. Aliment Pharmacol Ther 2023;57:549-64. [PMID: 36495561 DOI: 10.1111/apt.17309] [Reference Citation Analysis]
3 Campos-Madueno EI, Moradi M, Eddoubaji Y, Shahi F, Moradi S, Bernasconi OJ, Moser AI, Endimiani A. Intestinal colonization with multidrug-resistant Enterobacterales: screening, epidemiology, clinical impact, and strategies to decolonize carriers. Eur J Clin Microbiol Infect Dis 2023;42:229-54. [PMID: 36680641 DOI: 10.1007/s10096-023-04548-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Chauhan A, Garg M. Editorial: faecal microbiota transplantation for recurrent C. difficile infections-getting the support that is needed. Aliment Pharmacol Ther 2023;57:585-6. [PMID: 36786456 DOI: 10.1111/apt.17341] [Reference Citation Analysis]
5 Weir TL. Grand challenges: Actualizing the potential of the gut microbiome to address global nutrition challenges. Front Microbiomes 2023;2. [DOI: 10.3389/frmbi.2023.1146827] [Reference Citation Analysis]
6 Piao XM, Byun YJ, Zheng CM, Song SJ, Kang HW, Kim WT, Yun SJ. A New Treatment Landscape for RCC: Association of the Human Microbiome with Improved Outcomes in RCC. Cancers (Basel) 2023;15. [PMID: 36765892 DOI: 10.3390/cancers15030935] [Reference Citation Analysis]
7 Shin J. Fecal microbiota transplantation is not a magical treatment, but better too early than too late. Korean J Intern Med 2023;38:3-4. [PMID: 36596758 DOI: 10.3904/kjim.2022.377] [Reference Citation Analysis]
8 Wortelboer K, Koopen AM, Herrema H, de Vos WM, Nieuwdorp M, Kemper EM. From fecal microbiota transplantation toward next-generation beneficial microbes: The case of Anaerobutyricum soehngenii. Front Med (Lausanne) 2022;9:1077275. [PMID: 36544495 DOI: 10.3389/fmed.2022.1077275] [Reference Citation Analysis]
9 Wiese M, Schuren FHJ, Smits WK, Kuijper EJ, Ouwens A, Heerikhuisen M, Vigsnaes L, van den Broek TJ, de Boer P, Montijn RC, van der Vossen JMBM. 2’-Fucosyllactose inhibits proliferation of Clostridioides difficile ATCC 43599 in the CDi-screen, an in vitro model simulating Clostridioides difficile infection. Front Cell Infect Microbiol 2022;12. [DOI: 10.3389/fcimb.2022.991150] [Reference Citation Analysis]
10 Bénard MV, de Bruijn CMA, Fenneman AC, Wortelboer K, Zeevenhoven J, Rethans B, Herrema HJ, van Gool T, Nieuwdorp M, Benninga MA, Ponsioen CY. Challenges and costs of donor screening for fecal microbiota transplantations. PLoS One 2022;17:e0276323. [PMID: 36264933 DOI: 10.1371/journal.pone.0276323] [Reference Citation Analysis]
11 Stallmach A, Steube A, Stallhofer J, Grunert PC, Merkel U, Hartmann M. Fäkaler Mikrobiomtransfer – Indikationen, Risiken und Chancen. Innere Medizin 2022;63:1036-1042. [DOI: 10.1007/s00108-022-01399-5] [Reference Citation Analysis]
12 Xu H, Cao C, Ren Y, Weng S, Liu L, Guo C, Wang L, Han X, Ren J, Liu Z. Antitumor effects of fecal microbiota transplantation: Implications for microbiome modulation in cancer treatment. Front Immunol 2022;13:949490. [DOI: 10.3389/fimmu.2022.949490] [Reference Citation Analysis]
13 Quaranta G, Ianiro G, De Maio F, Guarnaccia A, Fancello G, Agrillo C, Iannarelli F, Bibbo S, Amedei A, Sanguinetti M, Cammarota G, Masucci L, Agrawal N. “Bacterial Consortium”: A Potential Evolution of Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection. BioMed Research International 2022;2022:1-9. [DOI: 10.1155/2022/5787373] [Reference Citation Analysis]
14 Lu G, Wang W, Li P, Wen Q, Cui B, Zhang F. Washed preparation of faecal microbiota changes the transplantation related safety, quantitative method and delivery. Microb Biotechnol 2022. [PMID: 35576458 DOI: 10.1111/1751-7915.14074] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
15 Ghani R, Mullish BH, Roberts LA, Davies FJ, Marchesi JR. The potential utility of fecal (or intestinal) microbiota transplantation in controlling infectious diseases. Gut Microbes 2022;14:2038856. [PMID: 35230889 DOI: 10.1080/19490976.2022.2038856] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
16 de Stefano MC, Mazzanti B, Vespasiano F, Lombardini L, Cardillo M. The Regulatory Approach for Faecal Microbiota Transplantation as Treatment for Clostridioides difficile Infection in Italy. Antibiotics 2022;11:480. [DOI: 10.3390/antibiotics11040480] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Chang L, Wei Y, Hashimoto K. Brain Research Bulletin: Special Issue: Brain–body communication in health and diseases, Brain–gut–microbiota axis in depression: A historical overview and future directions. Brain Research Bulletin 2022. [DOI: 10.1016/j.brainresbull.2022.02.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 22.0] [Reference Citation Analysis]
18 Di Pilato V, Morecchiato F, Rizzato C, Quaranta G, Fais R, Gandolfo C, Antonelli A, Cusi MG, Pistello M, Rossolini GM, Sanguinetti M, Lupetti A, Masucci L. Validation of Two Commercial Multiplex Real-Time PCR Assays for Detection of SARS-CoV-2 in Stool Donors for Fecal Microbiota Transplantation. Microorganisms 2022;10:284. [DOI: 10.3390/microorganisms10020284] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Ghani R, Mullish BH, Davies FJ, Marchesi JR. How to adapt an intestinal microbiota transplantation programme to reduce the risk of invasive multidrug-resistant infection. Clin Microbiol Infect 2021:S1198-743X(21)00633-9. [PMID: 34826617 DOI: 10.1016/j.cmi.2021.11.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Estevinho MM. Stools' donor recruitment, a challenge in pandemic times. United European Gastroenterol J 2021;9:993-4. [PMID: 34687164 DOI: 10.1002/ueg2.12168] [Reference Citation Analysis]